Venus Remedies has successfully obtained Marketing Authorizations (MAs) for a range of essential oncology drugs in Ukraine (Asia CIS). This includes PACLITAXEL in various strengths of 100mg/16.7mL, 260mg/43.3mL, 300mg/50mL and 30mg/5mL, OXALIPLATIN in concentrations of 50mg/10mL and 100mg/20mL and lRINOTECAN in formulations of 100mg/5mL and 40mg/2mL.

These approvals mark significant progress for Venus Remedies in expanding its market presence and providing access to critical medications for cancer patients in the region.

The company remains committed to its mission of delivering high quality pharmaceuticals to improve healthcare outcomes globally.